http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 08:34:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+to+Present+at+the+16th+Annual+East+Coast+IDEAS+Investor+Conference/26596031.html <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54546441&amp;newsitemid=20260603929812&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=5aaf548e1d274851424624df45e2a7ed" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will present at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.threepartadvisors.com%2Feast-coast&amp;esheet=54546441&amp;newsitemid=20260603929812&amp;lan=en-US&amp;anchor=East+Coast+IDEAS+Investor+Conference&amp;index=2&amp;md5=8f388d9a56da62e3434e5efe98decbd6" shape="rect">East Coast IDEAS Investor Conference</a> on Thursday, June 11, 2026, at The Westin Times Square in New York, NY. </p><p> IDEAS Conferences provide independent regional venues for quality companies to present their investment merits to influential audiences of investment professionals, offering investor-sponsored events designed to benefit regional investment communities. </p><p> Niagen Bioscience CEO, Rob Fried, will present on Thursday, http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+to+Present+at+the+16th+Annual+East+Coast+IDEAS+Investor+Conference/26596031.html Wed, 03 Jun 2026 08:34:00 -0400 NAGE O.02128141 http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+to+Present+at+the+16th+Annual+East+Coast+IDEAS+Investor+Conference/26596031.html <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54546441&amp;newsitemid=20260603929812&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=5aaf548e1d274851424624df45e2a7ed" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will present at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.threepartadvisors.com%2Feast-coast&amp;esheet=54546441&amp;newsitemid=20260603929812&amp;lan=en-US&amp;anchor=East+Coast+IDEAS+Investor+Conference&amp;index=2&amp;md5=8f388d9a56da62e3434e5efe98decbd6" shape="rect">East Coast IDEAS Investor Conference</a> on Thursday, June 11, 2026, at The Westin Times Square in New York, NY. </p><p> IDEAS Conferences provide independent regional venues for quality companies to present their investment merits to influential audiences of investment professionals, offering investor-sponsored events designed to benefit regional investment communities. </p><p> Niagen Bioscience CEO, Rob Fried, will present on Thursday, http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+to+Present+at+the+16th+Annual+East+Coast+IDEAS+Investor+Conference/26596031.html Wed, 03 Jun 2026 08:34:00 -0400 NAGE O.02128141 http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+to+Present+at+the+16th+Annual+East+Coast+IDEAS+Investor+Conference/26596031.html <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54546441&amp;newsitemid=20260603929812&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=5aaf548e1d274851424624df45e2a7ed" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will present at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.threepartadvisors.com%2Feast-coast&amp;esheet=54546441&amp;newsitemid=20260603929812&amp;lan=en-US&amp;anchor=East+Coast+IDEAS+Investor+Conference&amp;index=2&amp;md5=8f388d9a56da62e3434e5efe98decbd6" shape="rect">East Coast IDEAS Investor Conference</a> on Thursday, June 11, 2026, at The Westin Times Square in New York, NY. </p><p> IDEAS Conferences provide independent regional venues for quality companies to present their investment merits to influential audiences of investment professionals, offering investor-sponsored events designed to benefit regional investment communities. </p><p> Niagen Bioscience CEO, Rob Fried, will present on Thursday, http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+to+Present+at+the+16th+Annual+East+Coast+IDEAS+Investor+Conference/26596031.html Wed, 03 Jun 2026 08:34:00 -0400 NAGE O.02128141 http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+to+Present+at+the+16th+Annual+East+Coast+IDEAS+Investor+Conference/26596031.html <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54546441&amp;newsitemid=20260603929812&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=5aaf548e1d274851424624df45e2a7ed" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will present at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.threepartadvisors.com%2Feast-coast&amp;esheet=54546441&amp;newsitemid=20260603929812&amp;lan=en-US&amp;anchor=East+Coast+IDEAS+Investor+Conference&amp;index=2&amp;md5=8f388d9a56da62e3434e5efe98decbd6" shape="rect">East Coast IDEAS Investor Conference</a> on Thursday, June 11, 2026, at The Westin Times Square in New York, NY. </p><p> IDEAS Conferences provide independent regional venues for quality companies to present their investment merits to influential audiences of investment professionals, offering investor-sponsored events designed to benefit regional investment communities. </p><p> Niagen Bioscience CEO, Rob Fried, will present on Thursday, http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+to+Present+at+the+16th+Annual+East+Coast+IDEAS+Investor+Conference/26596031.html Wed, 03 Jun 2026 08:34:00 -0400 NAGE O.02128141 http://www.streetinsider.com/Corporate+News/Niagen+Bioscience+renames+research+program%2C+cites+300%2B+collaborations/26588211.html <p>Niagen Bioscience Inc. (NASDAQ: NAGE) announced it has renamed the ChromaDex External Research Program to the Niagen Research Program, according to a company statement.</p><p>The program has supported more than 300 research collaborations across institutions worldwide and contributed to over 45 published human clinical studies on Niagen, the company's nicotinamide riboside product, the statement said.</p><p>"The Niagen Research Program reflects both the maturity of the science and the scale of the global research community advancing it," said Rob Fried, CEO of Niagen Bioscience.</p><p>Through the program, investigators from institutions including Mayo Clinic, National Institutes of Health, Harvard University, MIT, and Cambridge University have http://www.streetinsider.com/Corporate+News/Niagen+Bioscience+renames+research+program%2C+cites+300%2B+collaborations/26588211.html Tue, 02 Jun 2026 08:33:30 -0400 NAGE http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html <p class="bwalignc"> <i>The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=c7459c66ac11b4183a6b4b27df86f3fc" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2Fpages%2Fhttps-www-niagenbioscience-com-pages-niagenresearchprogram&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Research+Program&amp;index=2&amp;md5=3e4cff9222f76744675cdb44d99d201a" shape="rect">Niagen Research Program</a>, reflecting the Company’s name evolution with a focus on http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html Tue, 02 Jun 2026 08:32:00 -0400 A.07309385 A.07880129 A.19655944 A.50214881 NAGE O.02128141 O.03307993 O.20043539 O.21200813 O.36851535 http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html <p class="bwalignc"> <i>The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=c7459c66ac11b4183a6b4b27df86f3fc" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2Fpages%2Fhttps-www-niagenbioscience-com-pages-niagenresearchprogram&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Research+Program&amp;index=2&amp;md5=3e4cff9222f76744675cdb44d99d201a" shape="rect">Niagen Research Program</a>, reflecting the Company’s name evolution with a focus on http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html Tue, 02 Jun 2026 08:32:00 -0400 A.07309385 A.07880129 A.19655944 A.50214881 NAGE O.02128141 O.03307993 O.20043539 O.21200813 O.36851535 http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html <p class="bwalignc"> <i>The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=c7459c66ac11b4183a6b4b27df86f3fc" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2Fpages%2Fhttps-www-niagenbioscience-com-pages-niagenresearchprogram&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Research+Program&amp;index=2&amp;md5=3e4cff9222f76744675cdb44d99d201a" shape="rect">Niagen Research Program</a>, reflecting the Company’s name evolution with a focus on http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html Tue, 02 Jun 2026 08:32:00 -0400 A.07309385 A.07880129 A.19655944 A.50214881 NAGE O.02128141 O.03307993 O.20043539 O.21200813 O.36851535 http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html <p class="bwalignc"> <i>The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=c7459c66ac11b4183a6b4b27df86f3fc" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2Fpages%2Fhttps-www-niagenbioscience-com-pages-niagenresearchprogram&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Research+Program&amp;index=2&amp;md5=3e4cff9222f76744675cdb44d99d201a" shape="rect">Niagen Research Program</a>, reflecting the Company’s name evolution with a focus on http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html Tue, 02 Jun 2026 08:32:00 -0400 A.07309385 A.07880129 A.19655944 A.50214881 NAGE O.02128141 O.03307993 O.20043539 O.21200813 O.36851535 http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html <p class="bwalignc"> <i>The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=c7459c66ac11b4183a6b4b27df86f3fc" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2Fpages%2Fhttps-www-niagenbioscience-com-pages-niagenresearchprogram&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Research+Program&amp;index=2&amp;md5=3e4cff9222f76744675cdb44d99d201a" shape="rect">Niagen Research Program</a>, reflecting the Company’s name evolution with a focus on http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html Tue, 02 Jun 2026 08:32:00 -0400 A.07309385 A.07880129 A.19655944 A.50214881 NAGE O.02128141 O.03307993 O.20043539 O.21200813 O.36851535 http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html <p class="bwalignc"> <i>The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=c7459c66ac11b4183a6b4b27df86f3fc" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2Fpages%2Fhttps-www-niagenbioscience-com-pages-niagenresearchprogram&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Research+Program&amp;index=2&amp;md5=3e4cff9222f76744675cdb44d99d201a" shape="rect">Niagen Research Program</a>, reflecting the Company’s name evolution with a focus on http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html Tue, 02 Jun 2026 08:32:00 -0400 A.07309385 A.07880129 A.19655944 A.50214881 NAGE O.02128141 O.03307993 O.20043539 O.21200813 O.36851535 http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html <p class="bwalignc"> <i>The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=c7459c66ac11b4183a6b4b27df86f3fc" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2Fpages%2Fhttps-www-niagenbioscience-com-pages-niagenresearchprogram&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Research+Program&amp;index=2&amp;md5=3e4cff9222f76744675cdb44d99d201a" shape="rect">Niagen Research Program</a>, reflecting the Company’s name evolution with a focus on http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html Tue, 02 Jun 2026 08:32:00 -0400 A.07309385 A.07880129 A.19655944 A.50214881 NAGE O.02128141 O.03307993 O.20043539 O.21200813 O.36851535 http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html <p class="bwalignc"> <i>The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=c7459c66ac11b4183a6b4b27df86f3fc" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2Fpages%2Fhttps-www-niagenbioscience-com-pages-niagenresearchprogram&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Research+Program&amp;index=2&amp;md5=3e4cff9222f76744675cdb44d99d201a" shape="rect">Niagen Research Program</a>, reflecting the Company’s name evolution with a focus on http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html Tue, 02 Jun 2026 08:32:00 -0400 A.07309385 A.07880129 A.19655944 A.50214881 NAGE O.02128141 O.03307993 O.20043539 O.21200813 O.36851535 http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html <p class="bwalignc"> <i>The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=c7459c66ac11b4183a6b4b27df86f3fc" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2Fpages%2Fhttps-www-niagenbioscience-com-pages-niagenresearchprogram&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Research+Program&amp;index=2&amp;md5=3e4cff9222f76744675cdb44d99d201a" shape="rect">Niagen Research Program</a>, reflecting the Company’s name evolution with a focus on http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html Tue, 02 Jun 2026 08:32:00 -0400 A.07309385 A.07880129 A.19655944 A.50214881 NAGE O.02128141 O.03307993 O.20043539 O.21200813 O.36851535 http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html <p class="bwalignc"> <i>The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=c7459c66ac11b4183a6b4b27df86f3fc" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2Fpages%2Fhttps-www-niagenbioscience-com-pages-niagenresearchprogram&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Research+Program&amp;index=2&amp;md5=3e4cff9222f76744675cdb44d99d201a" shape="rect">Niagen Research Program</a>, reflecting the Company’s name evolution with a focus on http://www.streetinsider.com/Press+Releases/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html Tue, 02 Jun 2026 08:32:00 -0400 A.07309385 A.07880129 A.19655944 A.50214881 NAGE O.02128141 O.03307993 O.20043539 O.21200813 O.36851535 http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html <p class="bwalignc"> <i>The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=c7459c66ac11b4183a6b4b27df86f3fc" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2Fpages%2Fhttps-www-niagenbioscience-com-pages-niagenresearchprogram&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Research+Program&amp;index=2&amp;md5=3e4cff9222f76744675cdb44d99d201a" shape="rect">Niagen Research Program</a>, reflecting the Company’s name evolution with a focus on http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html Tue, 02 Jun 2026 08:32:00 -0400 A.07309385 A.07880129 A.19655944 A.50214881 NAGE O.02128141 O.03307993 O.20043539 O.21200813 O.36851535 http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html <p class="bwalignc"> <i>The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=c7459c66ac11b4183a6b4b27df86f3fc" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2Fpages%2Fhttps-www-niagenbioscience-com-pages-niagenresearchprogram&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Research+Program&amp;index=2&amp;md5=3e4cff9222f76744675cdb44d99d201a" shape="rect">Niagen Research Program</a>, reflecting the Company’s name evolution with a focus on http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html Tue, 02 Jun 2026 08:32:00 -0400 A.07309385 A.07880129 A.19655944 A.50214881 NAGE O.02128141 O.03307993 O.20043539 O.21200813 O.36851535 http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html <p class="bwalignc"> <i>The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=c7459c66ac11b4183a6b4b27df86f3fc" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2Fpages%2Fhttps-www-niagenbioscience-com-pages-niagenresearchprogram&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Research+Program&amp;index=2&amp;md5=3e4cff9222f76744675cdb44d99d201a" shape="rect">Niagen Research Program</a>, reflecting the Company’s name evolution with a focus on http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html Tue, 02 Jun 2026 08:32:00 -0400 A.07309385 A.07880129 A.19655944 A.50214881 NAGE O.02128141 O.03307993 O.20043539 O.21200813 O.36851535 http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html <p class="bwalignc"> <i>The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=c7459c66ac11b4183a6b4b27df86f3fc" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2Fpages%2Fhttps-www-niagenbioscience-com-pages-niagenresearchprogram&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Research+Program&amp;index=2&amp;md5=3e4cff9222f76744675cdb44d99d201a" shape="rect">Niagen Research Program</a>, reflecting the Company’s name evolution with a focus on http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html Tue, 02 Jun 2026 08:32:00 -0400 A.07309385 A.07880129 A.19655944 A.50214881 NAGE O.02128141 O.03307993 O.20043539 O.21200813 O.36851535 http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html <p class="bwalignc"> <i>The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=c7459c66ac11b4183a6b4b27df86f3fc" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2Fpages%2Fhttps-www-niagenbioscience-com-pages-niagenresearchprogram&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Research+Program&amp;index=2&amp;md5=3e4cff9222f76744675cdb44d99d201a" shape="rect">Niagen Research Program</a>, reflecting the Company’s name evolution with a focus on http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html Tue, 02 Jun 2026 08:32:00 -0400 A.07309385 A.07880129 A.19655944 A.50214881 NAGE O.02128141 O.03307993 O.20043539 O.21200813 O.36851535 http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html <p class="bwalignc"> <i>The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=c7459c66ac11b4183a6b4b27df86f3fc" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2Fpages%2Fhttps-www-niagenbioscience-com-pages-niagenresearchprogram&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Research+Program&amp;index=2&amp;md5=3e4cff9222f76744675cdb44d99d201a" shape="rect">Niagen Research Program</a>, reflecting the Company’s name evolution with a focus on http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html Tue, 02 Jun 2026 08:32:00 -0400 A.07309385 A.07880129 A.19655944 A.50214881 NAGE O.02128141 O.03307993 O.20043539 O.21200813 O.36851535 http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html <p class="bwalignc"> <i>The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=c7459c66ac11b4183a6b4b27df86f3fc" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2Fpages%2Fhttps-www-niagenbioscience-com-pages-niagenresearchprogram&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Research+Program&amp;index=2&amp;md5=3e4cff9222f76744675cdb44d99d201a" shape="rect">Niagen Research Program</a>, reflecting the Company’s name evolution with a focus on http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html Tue, 02 Jun 2026 08:32:00 -0400 A.07309385 A.07880129 A.19655944 A.50214881 NAGE O.02128141 O.03307993 O.20043539 O.21200813 O.36851535 http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html <p class="bwalignc"> <i>The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=c7459c66ac11b4183a6b4b27df86f3fc" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2Fpages%2Fhttps-www-niagenbioscience-com-pages-niagenresearchprogram&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Research+Program&amp;index=2&amp;md5=3e4cff9222f76744675cdb44d99d201a" shape="rect">Niagen Research Program</a>, reflecting the Company’s name evolution with a focus on http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html Tue, 02 Jun 2026 08:32:00 -0400 A.07309385 A.07880129 A.19655944 A.50214881 NAGE O.02128141 O.03307993 O.20043539 O.21200813 O.36851535 http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html <p class="bwalignc"> <i>The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=c7459c66ac11b4183a6b4b27df86f3fc" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2Fpages%2Fhttps-www-niagenbioscience-com-pages-niagenresearchprogram&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Research+Program&amp;index=2&amp;md5=3e4cff9222f76744675cdb44d99d201a" shape="rect">Niagen Research Program</a>, reflecting the Company’s name evolution with a focus on http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html Tue, 02 Jun 2026 08:32:00 -0400 A.07309385 A.07880129 A.19655944 A.50214881 NAGE O.02128141 O.03307993 O.20043539 O.21200813 O.36851535 http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html <p class="bwalignc"> <i>The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=c7459c66ac11b4183a6b4b27df86f3fc" shape="rect">Niagen Bioscience, Inc.</a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2Fpages%2Fhttps-www-niagenbioscience-com-pages-niagenresearchprogram&amp;esheet=54543118&amp;newsitemid=20260528142655&amp;lan=en-US&amp;anchor=Niagen+Research+Program&amp;index=2&amp;md5=3e4cff9222f76744675cdb44d99d201a" shape="rect">Niagen Research Program</a>, reflecting the Company’s name evolution with a focus on http://www.streetinsider.com/Business+Wire/Niagen+Bioscience+Renames+ChromaDex+External+Research+Program+to+the+Niagen+Research+Program%2C+Strengthening+Position+as+the+Global+Leader+in+NAD%2B+Science/26588180.html Tue, 02 Jun 2026 08:32:00 -0400 A.07309385 A.07880129 A.19655944 A.50214881 NAGE O.02128141 O.03307993 O.20043539 O.21200813 O.36851535